Trevi Therapeutics Prices Stock Offering at $13 a Share

By Chris Stiles • Friday, April 17 14:01 • Permanent Link

Trevi Therapeutics priced its underwritten stock offering at $13.00 a share, raising about $150 million before fees and expenses from the sale of 11.6 million shares.

The company also gave underwriters a 30-day option to buy up to 1.74 million additional shares at the same price, which could lift the gross proceeds further if exercised.

The offering is smaller than the potential maximum that would result if the full greenshoe is taken up: 11.6 million shares at $13.00 equals $150.8 million, while the extra 1.74 million shares would add another $22.6 million.

Trevi said the shares are expected to close around April 20, 2026. All of the shares in the deal are being sold by the company itself. As a result of these announcements, the company's shares have moved 3.15% on the market, and are now trading at a price of $11.80. For the full picture, make sure to review Trevi Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.